AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03324438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Adherence Feedback
Description: 1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
Study NCT02565901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02565901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02565901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02565901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01776021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cranberry juice
Description: cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
Study NCT01776021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo beverage
Description: placebo beverage at a dose of one 8 oz. beverage per day for six months
Study NCT03391765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
Study NCT03391765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution for IV infusion on Day 15
Description: 0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
Study NCT02212444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthoses (DEFO)
Description: A patient customised dynamic elastomeric fabric orthoses (DEFO)
Study NCT02212444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off -the-shelf triplanar orthoses
Study NCT02259517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Study NCT02259517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Study NCT00963911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric screening tests
Description: The G-8 consists of eight items: patient age (>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score >=3 was considered to show impairment.
Study NCT00963911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional geriatric assessment
Description: Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
Study NCT00551070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00551070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00551070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT00551070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT03966053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Description: Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
Study NCT01073670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study NCT01073670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen & Indomethacin
Description: Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study NCT01073670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study NCT05011643 — intervention group
Intervention type: OTHER
Intervention: Moderate-intensity exercise
Description: Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
Study NCT02104362 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: exclusive single-fraction irradiation
Study NCT01750762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT03484676 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Titinium
Description: custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
Study NCT02056860 — intervention group
Intervention type: PROCEDURE
Intervention: Group 1 will receive 15 Hz
Description: Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
Study NCT02056860 — intervention group
Intervention type: PROCEDURE
Intervention: Group 2 will receive 30 Hz
Description: Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
Study NCT02056860 — intervention group
Intervention type: PROCEDURE
Intervention: Group 3 will receive 60 Hz
Description: Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
Study NCT02056860 — intervention group
Intervention type: PROCEDURE
Intervention: Group 4 will receive 100 Hz
Description: Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
Study NCT02056860 — intervention group
Intervention type: PROCEDURE
Intervention: Phase II Optimal Frequency
Description: Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
Study NCT02016404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium, high-potassium salt
Description: Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
Study NCT02016404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular salt
Description: Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
Study NCT02628002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill (Alter-G)
Description: Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
Study NCT02628002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treadmill/regadenoson
Description: Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
Study NCT03326310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression
Study NCT03326310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
Study NCT00485225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3270
Description: Transdermal Therapeutic System
Study NCT03996408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT03996408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT01124721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive computerized training for several days per week.
Study NCT01124721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training-placebo
Description: Cognitive training that only minimally increases in difficulty
Study NCT03083535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing
Description: Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
Study NCT03083535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Brushing
Description: Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
Study NCT03083535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aloe vera Massaging
Description: Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
Study NCT03083535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP with aloe vera massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
Study NCT01933295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Study NCT01933295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Study NCT01933295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy
Study NCT03873220 — intervention group
Intervention type: DEVICE
Intervention: Wrist Actigraphy Devices
Description: A watch-like wearable sensor
Study NCT03873220 — intervention group
Intervention type: DEVICE
Intervention: Sleep Monitor
Description: Remote Sensor
Study NCT03873220 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep Monitor
Study NCT03873220 — intervention group
Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study NCT00409695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Thymoglobulin (ATG)
Description: 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
Study NCT00409695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Thymoglobulin (ATG)
Description: 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
Study NCT01500330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cupping massage
Description: the upper back is covered in massage oil the cupping glass is drawn along the back muscles
Study NCT01500330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: standardized programme on muscle relaxation according to Jacobson
Study NCT02364180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electromyography (EMG)
Study NCT03873818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03873818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03887195 — intervention group
Intervention type: OTHER
Intervention: Training mandatory module about the therapeutic relationship
Description: The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination.
Study NCT03752541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
Study NCT01673009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
Study NCT03021486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: Given IV
Study NCT03021486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV
Study NCT03021486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02231138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot (AM)
Description: Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
Study NCT02979912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Lysate
Description: Eye drops of Platelet Lysate
Study NCT03021486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04185012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
Study NCT04185012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
Study NCT01969422 — intervention group
Intervention type: PROCEDURE
Intervention: observation
Description: intervention is the contact with online question answering serice ad subseudd
Study NCT01887470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose preparation
Study NCT01887470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split dose preparation
Study NCT04196998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Study NCT04196998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Study NCT04196998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study NCT01840553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sodium phosphate tablets
Study NCT01840553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study NCT01042028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus, Cetuximab, Irinotecan
Description: Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
Study NCT01042028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Oxaliplatine
Description: Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
Study NCT02998814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acid-etch
Description: acid-etch
Study NCT02998814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive
Description: Self etch (7th generation ) bonding agent
Study NCT02998814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etch-and-rinse adhesive
Description: Total etch bonding agent (5th generation)
Study NCT02998814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive after acid-etch
Description: acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
Study NCT03744468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Humanized IgG1-variant monoclonal antibody against TIM-3
Study NCT03744468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Humanized, IgG4-variant monoclonal antibody against PD-1
Study NCT03744468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Human anti LAG-3 IgG4-kappa antibody
Study NCT06452953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suanzaoren decoction
Description: The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver